ImpediMed Ltd
ASX:IPD
Intrinsic Value
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. [ Read More ]
The intrinsic value of one IPD stock under the Base Case scenario is 0.05 AUD. Compared to the current market price of 0.08 AUD, ImpediMed Ltd is Overvalued by 41%.
Valuation Backtest
ImpediMed Ltd
Run backtest to discover the historical profit from buying and selling IPD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ImpediMed Ltd
Current Assets | 41.5m |
Cash & Short-Term Investments | 36.9m |
Receivables | 2.7m |
Other Current Assets | 1.9m |
Non-Current Assets | 17.1m |
Long-Term Investments | 48k |
PP&E | 1.7m |
Intangibles | 15.4m |
Current Liabilities | 5.9m |
Accounts Payable | 2.5m |
Other Current Liabilities | 3.4m |
Non-Current Liabilities | 1.7m |
Long-Term Debt | 963k |
Other Non-Current Liabilities | 712k |
Earnings Waterfall
ImpediMed Ltd
Revenue
|
10.5m
AUD
|
Cost of Revenue
|
-1.4m
AUD
|
Gross Profit
|
9.1m
AUD
|
Operating Expenses
|
-29.8m
AUD
|
Operating Income
|
-20.7m
AUD
|
Other Expenses
|
1.3m
AUD
|
Net Income
|
-19.4m
AUD
|
Free Cash Flow Analysis
ImpediMed Ltd
IPD Profitability Score
Profitability Due Diligence
ImpediMed Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
ImpediMed Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
IPD Solvency Score
Solvency Due Diligence
ImpediMed Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
ImpediMed Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IPD Price Targets Summary
ImpediMed Ltd
According to Wall Street analysts, the average 1-year price target for IPD is 0.18 AUD with a low forecast of 0.14 AUD and a high forecast of 0.21 AUD.
Shareholder Return
IPD Price
ImpediMed Ltd
Average Annual Return | -14.61% |
Standard Deviation of Annual Returns | 40.76% |
Max Drawdown | -85% |
Market Capitalization | 161.9m AUD |
Shares Outstanding | 1 997 847 100 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
Contact
IPO
Employees
Officers
The intrinsic value of one IPD stock under the Base Case scenario is 0.05 AUD.
Compared to the current market price of 0.08 AUD, ImpediMed Ltd is Overvalued by 41%.